Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05221840 · ClinicalTrials.gov registry record · Phase 3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,051
- Enrollment target
- 20
- Study locations
NCT05221840 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,051 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05221840, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,051 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Durvalumab
- DRUG Monalizumab
- DRUG Oleclumab
Study Locations (20)
Maryland
- Research Site - Annapolis
- Research Site - Baltimore
- Research Site - Baltimore
- Research Site - Bethesda
Ohio
- Research Site - Cleveland
- Research Site - Cleveland
- Research Site - Maumee
Kentucky
- Research Site - Lexington
- Research Site - Louisville
California
- Research Site - San Diego
Connecticut
- Research Site - New Haven
Florida
- Research Site - Stuart
Illinois
- Research Site - Urbana
Indiana
- Research Site - New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,051 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2030-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05221840
The ClinicalTrials.gov registry entry for NCT05221840 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,051 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (60% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05221840 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Maryland, Ohio, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05221840 about?
NCT05221840 is a clinical study titled "A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer". This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who...
What is the current status of trial NCT05221840?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,051 participants. The study started on 2022-02-07. Estimated completion is 2030-07-02.
What conditions does trial NCT05221840 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05221840?
The interventions under investigation include: Placebo (OTHER), Durvalumab (DRUG), Monalizumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT05221840?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05221840 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.